DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-11 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Liska (EP 1956033 A1).
Regarding claims 1-11, Liska teaches a (meth)acrylamide compound (Synthesis Example 7) of the following formula:
PNG
media_image1.png
162
533
media_image1.png
Greyscale
Which is a reaction product of acrylic acid chloride (paragraphs [0021], [0033], [0035]), shown in blue, as compound (X) and the divalent alicyclic primary amine compound N,N'-(1,3-cyclohexylenedimethylene)bisacrylamide, shown in red, which is the claimed Formula 1-2, with the following structure:
PNG
media_image2.png
104
298
media_image2.png
Greyscale
The above (meth)acrylamide compound has a structure according to the following formulae:
PNG
media_image3.png
132
309
media_image3.png
Greyscale
And
(1a)
PNG
media_image4.png
89
185
media_image4.png
Greyscale
Where R1 and R2 are hydrogens R3 is formula (1a), where X1 and X2 are each a methylene (linking) group and Y is a 6-carbon alicyclic structure. R3 is formed by linking a methylene group, a divalent alicyclic hydrocarbon group, and a methylene group, as per claim 9. The molecular weight of the above (meth)acrylamide compound is 254 g/mol.
Claims 1 and 12-15 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Klee (US 20090043008 A1).
Regarding claims 1, and 12-15, Klee teaches dental adhesive comprising a monomer composition which comprises (meth)acrylamide compounds which comprise a cyclic structure and a (meth)acrylamide group having the following structures:
PNG
media_image5.png
96
166
media_image5.png
Greyscale
and
PNG
media_image6.png
105
196
media_image6.png
Greyscale
And also comprises a polymerization initiator (claims 1 and 15).
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure:
Huchthausen (Reactivity of Acrylamides Causes Cytotoxicity and Activates Oxidative Stress Response) discusses acrylamide compounds and their effect in applications adhesives.
Antheunis (US 20120024697 A1) teaches a curable composition comprising isophorone diacrylamide, which is an acrylamide based on formula (1-3) of claim 3.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KOLTON JONES whose telephone number is (571)272-9802. The examiner can normally be reached Generally Monday-Friday 8:00 am - 5:00 pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Del Sole can be reached at (517)272-1130. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KOLTON JONES/Examiner, Art Unit 1763 /JOSEPH S DEL SOLE/Supervisory Patent Examiner, Art Unit 1763
Prosecution Insights